For the last four years, obesity drug development has been an arms race over one number: total weight loss percentage. Semaglutide hit 16%. Tirzepatide reached 22%. Retatrutide promised maybe 30% at the highest dose.
This week Lilly released early data that flips that script. They combined just 5 mg of tirzepatide with 3 mg of eloralintide, a new investigational amylin drug, and patients lost 17% of their body weight in 16 weeks.
The cohort on 5 mg tirzepatide alone lost about 10%. The number that matters is not the 17. It is the 5. Because Lilly did not need 15 mg of Zepbound to get near-retatrutide results, and that opens a question nobody was asking six months ago: what if the future is not about cranking doses higher?
What the mouse study actually tells us
Researchers published a study in Nature this week involving 20-month-old female mice, roughly equivalent to starting treatment late in life. They began treating them with semaglutide. The untreated mice lived a median of 742 days. The semaglutide-treated mice lived 834 days, a 12% increase in median lifespan.
Before anyone turns this into a longevity marketing pitch, the researchers asked the obvious follow-up: did the mice live longer because of semaglutide, or just because they ate less?
They compared the semaglutide group with another group of mice eating about 24% fewer calories, roughly matching the food intake reduction the drug produced. Much of the longevity benefit looked very similar.
But not all of it. The semaglutide-treated mice did better than the calorie-restricted mice in spatial memory, exploratory behavior and glucose tolerance. The calorie-restricted mice responded to eating less by reducing daytime energy expenditure. The semaglutide-treated animals largely did not.
That metabolic adaptation, where your body pulls back when you eat less, is something anyone who has tried to lose weight recognizes. The study does not prove semaglutide prevents it in humans. But it raises a different question: what else are these medications doing that we have not fully appreciated yet?
The $310,000 muscle drug nobody will get
The FDA approved apitegromab, now branded Assembled, this week. It was not approved for obesity. It was approved for a rare subset of people with spinal muscular atrophy, maybe 25,000 people total. The price is over $310,000 a year.
The obesity connection is a phase 2 trial called Embrace. Researchers gave 102 adults with overweight or obesity either tirzepatide plus apitegromab, or tirzepatide plus placebo. After 24 weeks, total weight loss was similar in both groups. But the tirzepatide-alone group lost 3.5 kg of lean mass compared with about 1.6 kg in the apitegromab group, roughly 55% greater lean mass retention.
Lean mass is not exactly the same thing as skeletal muscle. DXA measurements include muscle, but also water, organs and other non-fat tissue. This small phase 2 study does not tell us whether that difference produces better strength, physical function or long-term outcomes.
But the concept is compelling. Instead of asking only how much weight a medication can remove, researchers are beginning to ask whether we can manipulate the kind of weight that gets removed.
Lilly has been interested in this for years. They acquired a company called Versanis Bio for around $2 billion. It has a muscle-targeting agent called bimagrumab, now being developed in combination with tirzepatide. It works completely differently than apitegromab, but the goal is the same: improved body composition during weight loss.
Your chances of getting apitegromab off-label are essentially zero. Not just because of the price. It is a biologic, so it cannot be compounded. And it requires IV administration at a doctor's office. Convincing an insurance company to cover a newly approved six-figure biologic for an indication it does not have yet would be, let's say, quite the adventure.
Imagine two people both lose 50 pounds on a medication. One loses 35 pounds of fat and 15 pounds of lean mass while the other loses 45 pounds of fat and only five pounds of lean mass. The bathroom scale would tell you those outcomes are identical. Physiologically they are very different.On The Pen™ GLP-1 News
Why this matters if you haven’t started yet: If biologics become part of obesity combination therapy, the usual generic competition pipeline does not apply. You get biosimilars instead, which are highly similar to the reference biologic but much more complicated and expensive to develop and approve.
The retatrutide classification fight that matters more than retatrutide
Lilly and the FDA are scheduled for oral arguments before the seventh circuit on September 24th over how retatrutide should be classified: as a biologic or a conventional drug.
The classification affects exclusivity, competition and the environment surrounding compounded versions of the molecule. Biologics can receive up to 12 years of statutory exclusivity. Conventional drugs follow a much shorter framework, typically about five years.
Retatrutide is not FDA approved yet. That is what makes this so interesting. The legal fight is happening now to build a moat around the drug before it even reaches the market, because the non-branded market for retatrutide is already massive. Millions of people have tried research-grade versions. Compounded versions are available.
The outcome will have consequences long after retatrutide finally reaches the market, and potentially affects how the biologics definition itself gets applied by the FDA.
The illicit warehouse and what it means
Last year, Britain's medicines and healthcare products regulatory agency raided what it described as the first illicit weight loss medicine production facility discovered in the UK. Authorities said they found raw chemical ingredients, sophisticated manufacturing equipment, tens of thousands of empty weight loss pens and more than 2,000 unlicensed retatrutide pens waiting to be shipped.
An illicit warehouse manufacturing unlicensed product is not the same as regulated compounding pharmacies. Lumping those two together does not help the conversation. But it does demonstrate something drug companies and regulators cannot ignore: the demand is not going to disappear because the approved product is not available yet.
People are seeking this out. They are buying it from bodegas in New York City, swap meets in Ohio, even barbers. The demand goes somewhere, and it goes to wherever an option exists.
The tension is undeniable. Regulators have an obligation to protect patients from contaminated, counterfeit or incorrectly dosed drugs. Policy makers also have to recognize what happens when enormous patient demand collides with a completely broken system, or prices and access barriers people cannot overcome.
If reat were pond water and pond water worked like retatrutide did, people would inject it.On The Pen™ GLP-1 News
The Lilly versus Mochi ruling and where the line gets drawn
On September 8th, a judge partially granted and partially denied Mochi Health's latest motion to dismiss in the Lilly lawsuit. Lilly was not successful in extending their false advertising conspiracy theory to Mochi Medical and Truepill. But the judge allowed Lilly's California unfair competition law theory against Truepill involving allegations around the corporate practice of medicine to continue.
Lilly alleges that the business, medical and pharmacy operations were not as independent as they appeared on paper. Lilly also alleged that Truepill filed large numbers of identical prescriptions despite compounded medications being presented as individualized treatments, essentially the mass production of individualized medicine, which is not allowed under 503A regulations.
These remain allegations, not facts. But Lilly may now get a closer look through discovery at internal communications, procedures and relationships that could help establish who is actually controlling the medical and pharmacy decisions.
Here is the tension. Lilly says telehealth providers available through its own Lilly Direct platform are independent, that they exercise their own clinical judgment and are not incentivized to prescribe Lilly products. But those telehealth companies still receive a massive commercial benefit of being presented to patients inside the Lilly Direct ecosystem.
That does not automatically mean Lilly controls their prescribing. But it does raise the question: where exactly should we draw the line between a commercially valuable relationship surrounding health care and improper influence over medical care? If you are a telehealth company listed on Lilly Direct, it is pretty hard to argue that you do not have a financial incentive in making sure Zepbound is the product getting prescribed most often.
What happens when you do not need 15 mg
Back to the 5 mg. Lilly combined 5 mg of tirzepatide with 3 mg of eloralintide and got 17% body weight loss in 16 weeks. The question is whether this combination could eventually deliver something approaching retatrutide-like efficacy with a different, potentially more tolerable side effect profile.
All the data on eloralintide is early. At 48 weeks as a monotherapy, eloralintide hit 20% body weight loss by itself. What it can do for patients when combined with tirzepatide at higher doses is unknown.
At 12 mg, retatrutide produced spectacular numbers, 28.3% weight loss using the efficacy estimate. But the gastrointestinal side effects and increased heart rate were pretty high at that dose. You have to wonder how many people are going to be able to get to that high dose in the real world.
Meanwhile, Lilly is suddenly talking quite a bit about the other end of the retatrutide dose curve. Just 4 mg of retatrutide, one dose escalation from the starting dose of 2 mg, produced about 19% weight loss at 48 weeks. That is tirzepatide-level efficacy at just 4 mg of retatrutide.
A Lilly executive speaking this past weekend described it as roughly tirzepatide-like efficacy with very good tolerability, and specifically suggested that lower-dose retatrutide could have a role for people just entering obesity treatment. That is a significant change in how most of us have thought about retatrutide. Everybody assumed retatrutide would be the drug you graduate to when Zepbound is not enough, the nuclear option.
But Lilly seems increasingly interested in retatrutide playing a role at both ends of obesity treatment. You have to wonder if it is because the efficacy of tirzepatide and eloralintide will eclipse retatrutide's high dose with fewer side effects, ultimately making the thought of enduring the side effects with high-dose retatrutide less palatable for some people.
The efficacy estimate is like the dating profile. Great lighting, perfect angle, maybe even an image that was run through AI first. The treatment policy estimate is actually closer to who actually shows up for the date.On The Pen™ GLP-1 News
Why this matters if you haven’t started yet: The treatment policy estimate reflects how things work out in the real world, closer to real-world results than the efficacy estimate, which reflects ideal trial conditions.
The next generation of these medications is about the quality of weight loss, the quality of life while you are on the medication. These are things we did not have the luxury of considering over the last five years.
The mentality of prescribers and patients may have to start to change a little bit. Because these molecules are getting more interesting, and the arms race may be shifting from how much you lose to what you lose and how you feel while you are losing it.
Questions people ask
What is eloralintide and how does it work with tirzepatide?
Eloralintide is an investigational amylin drug that Lilly is testing in combination with tirzepatide. In early data, 5 mg tirzepatide plus 3 mg eloralintide produced 17% weight loss in 16 weeks, compared to 10% with tirzepatide alone. As a monotherapy at 48 weeks, eloralintide produced 20% weight loss.
Will retatrutide be classified as a biologic or a conventional drug?
That is being decided in court. Lilly and the FDA are scheduled for oral arguments on September 24th. If classified as a biologic, retatrutide could receive up to 12 years of statutory exclusivity instead of the roughly five years for conventional drugs. The classification also affects competition and compounding.
Can I get apitegromab off-label for muscle preservation on a GLP-1?
No. Apitegromab costs over $310,000 a year, was approved only for spinal muscular atrophy, is a biologic that cannot be compounded, and requires IV administration at a doctor's office. Convincing insurance to cover it off-label for obesity would be nearly impossible.
On The Pen is an independent GLP-1 news channel hosted by Dave Napman, who covers obesity drug development, compounding, regulatory battles and clinical trial data for patients on or considering these medications. 46,807 views on the original video.
Watch the original on YouTube →